Hyderabad, Aug 19 : Dr Reddy’s Laboratories Limited on Monday said that it has launched Versavo (bevacizumab), a biosimilar of Roche’s Avastin in India.
It would be used for treatment of several types of cancers (metastatic colorectal cancer, non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, cervical cancer, metastatic breast cancer and epithelial ovarian, fallopian tube and primary peritoneal cancer).
Dr Reddy’s Versavo is available in strengths of 100 mg and 400 mg single use vials, a company statement here said.
Commenting on the launch, MV Ramana, CEO - India and Emerging Markets, Dr Reddy’s Laboratories, said, “We regard the good health of our patients as our responsibility and are committed to ensure that they always have access to the medicines they need. The launch of Versavo® is another step in that journey and helps strengthen our Oncology portfolio.”
Dr Raymond De Vré, Global Head, Biologics, Dr Reddy’s Laboratories added “Versavo will help improve access to high quality therapy at an affordable cost, addressing the needs of patients with different cancers in India.”
Avastin and its biosimilars had India sales of approximately Rs 223 crore MAT for the most recent twelve months ending in December 2018, according to Ipsos.
Dr Reddy’s now has six biosimilar products commercialized in India and various emerging markets and an active development pipeline of several biosimilar products in the oncology and immunology space, the statement added.(UNI)